Yaseen M Arabi1, Ayed Y Asiri1, Abdullah M Assiri1, Hanan H Balkhy1, Ali Al Bshabshe1, Majed Al Jeraisy1, Yasser Mandourah1, Mohamed H A Azzam1, Abdulhadi M Bin Eshaq1, Sameera Al Johani1, Shmeylan Al Harbi1, Hani A A Jokhdar1, Ahmad M Deeb1, Ziad A Memish1, Jesna Jose1, Sameeh Ghazal1, Sarah Al Faraj1, Ghaleb A Al Mekhlafi1, Nisreen M Sherbeeni1, Fatehi E Elzein1, Fahad Al-Hameed1, Asim Al Saedi1, Naif K Alharbi1, Robert A Fowler1, Frederick G Hayden1, Abdulaziz Al-Dawood1, Mohamed Abdelzaher1, Wail Bajhmom1, Badriah M AlMutairi1, Mohamed A Hussein1, Adel Alothman1. 1. From the Intensive Care Department (Y.M.A., A.A.-D.) and the Departments of Infection Prevention and Control (H.H.B.), Pathology and Laboratory Medicine (S.A.J.), Pharmaceutical Care (S.A.H.), and Medicine (A.A.), King Abdulaziz Medical City, Ministry of National Guard Health Affairs, the College of Medicine (Y.M.A., S.A.J., A.A.-D., A.A.) and the College of Pharmacy (M.A.J., S.A.H.), King Saud bin Abdulaziz University for Health Sciences, Prince Mohammed bin Abdulaziz Hospital (A.Y.A., Z.A.M., S.G., S.A.F.), Infection Prevention and Control, Preventive Health (A.M.A.), and Deputyship for Public Health (H.A.A.J.), Ministry of Health, Clinical Trials Services (M.A.J., A.M.D., B.M.A.) and the Departments of Biostatistics and Informatics (J.J., M.A.H.) and Infectious Disease Research (N.K.A.), King Abdullah International Medical Research Center, the Military Medical Services, Ministry of Defense (Y.M.), the Department of Intensive Care Services (G.A.A.M.), and the Infectious Diseases Division (N.M.S., F.E.E.), Prince Sultan Military Medical City, and the College of Medicine, Alfaisal University (Z.A.M.), Riyadh, the Department of Critical Care Medicine, King Khalid University, Aseer Central Hospital, Abha (A.A.B.), Medical Services (M.H.A.A.) and the Department of Critical Care Medicine (M.A.), King Abdullah Medical Complex, the Health Directorate, Ministry of Health (M.H.A.A.), and the Internal Medicine Department, King Fahad General Hospital, Ministry of Health (W.B.), the Intensive Care Department (F.A.-H.) and the Department of Infection Prevention and Control (A.A.S.), Ministry of National Guard Health Affairs, and the College of Medicine and King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center (F.A.-H., A.A.S.), Jeddah, and the Intensive Care Department, King Khalid Hospital, Najran (A.M.B.E.) - all in Saudi Arabia; the World Health Organization, Geneva (H.H.B.); the Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta (Z.A.M.); the Departments of Critical Care Medicine and Medicine, Sunnybrook Hospital, and the Institute of Health Policy Management and Evaluation, University of Toronto, Toronto (R.A.F.); and the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.).
Abstract
BACKGROUND: Whether combined treatment with recombinant interferon beta-1b and lopinavir-ritonavir reduces mortality among patients hospitalized with Middle East respiratory syndrome (MERS) is unclear. METHODS: We conducted a randomized, adaptive, double-blind, placebo-controlled trial that enrolled patients at nine sites in Saudi Arabia. Hospitalized adults with laboratory-confirmed MERS were randomly assigned to receive recombinant interferon beta-1bplus lopinavir-ritonavir (intervention) or placebo for 14 days. The primary outcome was 90-day all-cause mortality, with a one-sided P-value threshold of 0.025. Prespecified subgroup analyses and safety analyses were conducted. Because of the pandemic of coronavirus disease 2019, the data and safety monitoring board requested an unplanned interim analysis and subsequently recommended the termination of enrollment and the reporting of the results. RESULTS:A total of 95 patients were enrolled; 43 patients were assigned to the intervention group and 52 to the placebo group. A total of 12 patients (28%) in the intervention group and 23 (44%) in the placebo group died by day 90. The analysis of the primary outcome, with accounting for the adaptive design, yielded a risk difference of -19 percentage points (upper boundary of the 97.5% confidence interval [CI], -3; one-sided P = 0.024). In a prespecified subgroup analysis, treatment within 7 days after symptom onset led to lower 90-day mortality than use of placebo (relative risk, 0.19; 95% CI, 0.05 to 0.75), whereas later treatment did not. Serious adverse events occurred in 4 patients (9%) in the intervention group and in 10 (19%) in the placebo group. CONCLUSIONS: A combination of recombinant interferon beta-1b and lopinavir-ritonavir led to lower mortality than placebo among patients who had been hospitalized with laboratory-confirmed MERS. The effect was greatest when treatment was started within 7 days after symptom onset. (Funded by the King Abdullah International Medical Research Center; MIRACLE ClinicalTrials.gov number, NCT02845843.).
RCT Entities:
BACKGROUND: Whether combined treatment with recombinant interferon beta-1b and lopinavir-ritonavir reduces mortality among patients hospitalized with Middle East respiratory syndrome (MERS) is unclear. METHODS: We conducted a randomized, adaptive, double-blind, placebo-controlled trial that enrolled patients at nine sites in Saudi Arabia. Hospitalized adults with laboratory-confirmed MERS were randomly assigned to receive recombinant interferon beta-1b plus lopinavir-ritonavir (intervention) or placebo for 14 days. The primary outcome was 90-day all-cause mortality, with a one-sided P-value threshold of 0.025. Prespecified subgroup analyses and safety analyses were conducted. Because of the pandemic of coronavirus disease 2019, the data and safety monitoring board requested an unplanned interim analysis and subsequently recommended the termination of enrollment and the reporting of the results. RESULTS: A total of 95 patients were enrolled; 43 patients were assigned to the intervention group and 52 to the placebo group. A total of 12 patients (28%) in the intervention group and 23 (44%) in the placebo group died by day 90. The analysis of the primary outcome, with accounting for the adaptive design, yielded a risk difference of -19 percentage points (upper boundary of the 97.5% confidence interval [CI], -3; one-sided P = 0.024). In a prespecified subgroup analysis, treatment within 7 days after symptom onset led to lower 90-day mortality than use of placebo (relative risk, 0.19; 95% CI, 0.05 to 0.75), whereas later treatment did not. Serious adverse events occurred in 4 patients (9%) in the intervention group and in 10 (19%) in the placebo group. CONCLUSIONS: A combination of recombinant interferon beta-1b and lopinavir-ritonavir led to lower mortality than placebo among patients who had been hospitalized with laboratory-confirmed MERS. The effect was greatest when treatment was started within 7 days after symptom onset. (Funded by the King Abdullah International Medical Research Center; MIRACLE ClinicalTrials.gov number, NCT02845843.).
Authors: Maria P Sormani; Nicola De Rossi; Irene Schiavetti; Luca Carmisciano; Cinzia Cordioli; Lucia Moiola; Marta Radaelli; Paolo Immovilli; Marco Capobianco; Maria Trojano; Paola Zaratin; Gioacchino Tedeschi; Giancarlo Comi; Mario A Battaglia; Francesco Patti; Marco Salvetti Journal: Ann Neurol Date: 2021-02-09 Impact factor: 10.422
Authors: Jesna Jose; Hasan M Al-Dorzi; Awad Al-Omari; Yasser Mandourah; Fahad Al-Hameed; Musharaf Sadat; Eman Al Qasim; Basem Alraddadi; Abdulrahman Al Harthy; Ghaleb A Al Mekhlafi; Abdullah Almotairi; Kasim Al Khatib; Ahmed Abdulmomen; Ismael Qushmaq; Anees A Sindi; Ahmed Mady; Othman Solaiman; Rajaa Al-Raddadi; Khalid Maghrabi; Ahmed Ragab; Ayman Kharaba; Sarah Shalhoub; Abdulsalam M Al-Aithan; Gajendra K Vishwakarma; Atanu Bhattacharjee; Yaseen M Arabi Journal: BMC Infect Dis Date: 2021-01-19 Impact factor: 3.090
Authors: Donald C Vinh; Laurent Abel; Paul Bastard; Matthew P Cheng; Antonio Condino-Neto; Peter K Gregersen; Filomeen Haerynck; Maria-Pia Cicalese; David Hagin; Pere Soler-Palacín; Anna M Planas; Aurora Pujol; Luigi D Notarangelo; Qian Zhang; Helen C Su; Jean-Laurent Casanova; Isabelle Meyts Journal: J Clin Immunol Date: 2021-06-08 Impact factor: 8.542
Authors: Alejandro Krolewiecki; Adrián Lifschitz; Matías Moragas; Marina Travacio; Ricardo Valentini; Daniel F Alonso; Rubén Solari; Marcelo A Tinelli; Rubén O Cimino; Luis Álvarez; Pedro E Fleitas; Laura Ceballos; Marcelo Golemba; Florencia Fernández; Diego Fernández de Oliveira; German Astudillo; Inés Baeck; Javier Farina; Georgina A Cardama; Andrea Mangano; Eduardo Spitzer; Silvia Gold; Carlos Lanusse Journal: EClinicalMedicine Date: 2021-06-18
Authors: Yaseen M Arabi; Anthony C Gordon; Lennie P G Derde; Alistair D Nichol; Srinivas Murthy; Farah Al Beidh; Djillali Annane; Lolowa Al Swaidan; Abi Beane; Richard Beasley; Lindsay R Berry; Zahra Bhimani; Marc J M Bonten; Charlotte A Bradbury; Frank M Brunkhorst; Meredith Buxton; Adrian Buzgau; Allen Cheng; Menno De Jong; Michelle A Detry; Eamon J Duffy; Lise J Estcourt; Mark Fitzgerald; Rob Fowler; Timothy D Girard; Ewan C Goligher; Herman Goossens; Rashan Haniffa; Alisa M Higgins; Thomas E Hills; Christopher M Horvat; David T Huang; Andrew J King; Francois Lamontagne; Patrick R Lawler; Roger Lewis; Kelsey Linstrum; Edward Litton; Elizabeth Lorenzi; Salim Malakouti; Daniel F McAuley; Anna McGlothlin; Shay Mcguinness; Bryan J McVerry; Stephanie K Montgomery; Susan C Morpeth; Paul R Mouncey; Katrina Orr; Rachael Parke; Jane C Parker; Asad E Patanwala; Kathryn M Rowan; Marlene S Santos; Christina T Saunders; Christopher W Seymour; Manu Shankar-Hari; Steven Y C Tong; Alexis F Turgeon; Anne M Turner; Frank Leo Van de Veerdonk; Ryan Zarychanski; Cameron Green; Scott Berry; John C Marshall; Colin McArthur; Derek C Angus; Steven A Webb Journal: Intensive Care Med Date: 2021-07-12 Impact factor: 17.440